This is a preview of subscription content, log in via an institution to check access.
Notes
CD26 antigen inhibitors
2015 US dollars
Reference
Kwon CS, et al. Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes. BMC Health Services Research : 1 Feb 2018. Available from: URL: https://doi.org/10.1186/s12913-018-2860-0
Rights and permissions
About this article
Cite this article
Metformin + DPP-4i cost effective for second-line treatment. PharmacoEcon Outcomes News 797, 23 (2018). https://doi.org/10.1007/s40274-018-4732-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-018-4732-6